

Product datasheet for TR304880

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

DUSP19 Human shRNA Plasmid Kit (Locus ID 142679)

Product data:

Product Type: shRNA Plasmids

Product Name: DUSP19 Human shRNA Plasmid Kit (Locus ID 142679)

Locus ID: 142679

Synonyms: DUSP17; LMWDSP3; SKRP1; TS-DSP1

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Format:

Retroviral plasmids

Components: DUSP19 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

142679). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

RefSeq: NM 001142314, NM 001321519, NM 080876, NR 135688, NM 080876.1, NM 080876.2,

NM 080876.3, NM 001142314.1, BC035000, BC035000.1, BC093958, BC112005, BC143337,

NM 001142314.2, NM 080876.4

UniProt ID: Q8WTR2

Summary: Dual-specificity phosphatases (DUSPs) constitute a large heterogeneous subgroup of the type

I cysteine-based protein-tyrosine phosphatase superfamily. DUSPs are characterized by their ability to dephosphorylate both tyrosine and serine/threonine residues. They have been implicated as major modulators of critical signaling pathways. DUSP19 contains a variation of the consensus DUSP C-terminal catalytic domain, with the last serine residue replaced by alanine, and lacks the N-terminal CH2 domain found in the MKP (mitogen-activated protein kinase phosphatase) class of DUSPs (see MIM 600714) (summary by Patterson et al., 2009

[PubMed 19228121]).[supplied by OMIM, Dec 2009]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).